Published in Hepatitis Weekly, December 17th, 2001
Doctors in Japan say that based on murine models, the copper chelating agent trientine dihydrochloride could be used for reducing angiogenesis in hepatocellular carcinoma (HCC), one of the most common forms of cancer in the world. If so, the thousands of patients who develop HCC each year, whether due to liver cirrhosis, viral hepatitis, alcohol use, or liver toxins, would profit from the new treatment strategy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.